IDEAYA Biosciences
ShareCopied to clipboardIDEAYA Biosciences is a company. It is a public company in South San Francisco, the United States. It was founded in 2015 and its current CEO is Yujiro S. Hata. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: South San Francisco
- country: United States
- employees: 131 people
- revenues: 7M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2015
- CEO: Yujiro S. Hata
- ESG score: 69.43 / 100
See more facts
Extract data
Download datasets about IDEAYA Biosciences:
Dataset of stocks from IDEAYA Biosciences:
IDEAYA Biosciences is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in South San Francisco and 3,456,808 companies in our database.
Talking Points
- 51-200 employees Headquarters South San Francisco, California Type Public Company Founded 2015 Specialties Synthetic Lethality and Precision Medicine Locations Primary 7000 Shoreline Court 350...
- IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.